<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20200521047530N3</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-08-25</date_registration>
      <primary_sponsor>Tehran University of Medical Sciences</primary_sponsor>
      <public_title>Comparative study of analgesic quality in two methods of bilateral ilioinguinal block and caudal block</public_title>
      <acronym></acronym>
      <scientific_title>Comparative study of analgesic quality in two methods of bilateral illioinguinal block and caudal block with rupivacaine 0.2% in patients aged 3 to 8 years undergoing bilateral inguinal hernia surgery under general anesthesia in the Childern's Medical Center Hospital, 2021-22</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-06-22</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>66</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/56507</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: The sample will be identified by the randomization (restricted randomization) block method with 6 blocks and using a random number table of Random Allocation Software. The randomization tool is the random sequence generation software version 2.0, it will be available from the following address:(http://random.allocation software, version 2.0). Allocation concealment will be used to execute random sequences on participants. Each random sequence generated will be recorded on a card and the cards will be sealed in opaque envelopes. In order to maintain a random sequence, the envelopes are numbered in the same way on the outer surface, and finally the letter envelopes are glued and placed in a box respectively. Registration of participants, based on the order of entry of eligible participants into study, one of the envelopes of the letter is opened in order and the assigned group of the participant is revealed, Blinding description: A person who records the severity of pain and the patient does not know the type of block. The double blindness of the study will be done this way.</study_design>
      <phase>3</phase>
      <hc_freetext>Bilateral inguinal hernia surgery.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: Patient under bilateral ilioinguinal block with rupivacaine 0.2%( manufactured by MOLTENI farmaceutici) under ultrasound guide. After determining the sedation score according to Ramsay criteria, patients are directed to the operating room. After installing standard monitoring equipment and obtaining a peripheral vein, 2 mg/kg sodium thiopental and 1 μg/kg fentanyl m is prescribed. Induction of anesthesia will be done by mapleson and under spontaneous inhalation. sevoflurane 8% and 100% oxgygen will be used in induction. After endotracheal tube insertion, maintenance of anesthesia will be provided by 100% oxygen and isoflurane 2.5%. After induction of anesthesia, heart rate and mean arterial pressure will be measured and recorded.In performing ilio-inguinal block, the child is in the supine position and after prep and drape a short 24G needle will be used. Rupivacaine 0.2% at a dose of 0.1 ml / kg will be used for drug injection. In case of increased heart rate or systolic blood pressure after incision by more than 20% of basal values, fentanyl will be repeated and recorded at a dose of 1 μg /kg. After surgery, the patient's pain intensity will be assessed using the CHEOPS criteria and the delirium score will be assessed by PAED score. In post anesthesia care unit, patients with CHEOPS pain score greater than 10 will be prescribed 1 of fentanyl  μg /kg.Rupivacaine is from the Bioindustria L.i.m.s.p.a brand. Intervention 2: Intervention group 2: Patients under caudal block with rupivacaine 0.2%. After determining the sedation score according to Ramsay criteria, patients are directed to the operating room. After installing standard monitoring equipment and obtaining a peripheral vein, 2 mg/kg sodium thiopental and 1 μg/kg fentanyl m is prescribed. Induction of anesthesia will be done by mapleson and under spontaneous inhalation. sevoflurane 8% and 100% oxgygen will be used in induction. After endotracheal tube insertion, maintenance of anesthesia will be provided by 100% oxygen and isoflurane 2.5%. After induction of anesthesia, heart rate and mean arterial pressure will be measured and recorded./In performing ilio-inguinal block, the child is in the supine position and after prep and drape a short 24G needle will be used. Rupivacaine 0.2% at a dose of 0.1 ml. In the second group, the child is in a lateral position,The hip will flex and the lower leg will flex. After prep and drape, a short 24G needle was used Rupivacaine 0.2% at a dose of 1 ml / kg will be used.In case of increased heart rate or systolic blood pressure after incision by more than 20% of basal values, fentanyl will be repeated and recorded at a dose of 1 μg /kg. After surgery, the patient's pain intensity will be assessed using the CHEOPS criteria and the delirium score will be assessed by PAED score. In post anesthesia care unit, patients with CHEOPS pain score greater than 10 will be prescribed 1 of fentanyl  μg /kg.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The documents will be published in general and in the form of articles.

When:
The data will be provided after the publication of the article.

To whom:
Researchers at academic institutions can generally access study data.

Conditions:
Researchers are allowed to use the data only by citing the source and referring to the present study.

Where to obtain:
Dr. Nima Nazari/ E-mail: Nima.nazari1366@gmail.com

How to obtain:
After requesting the person in charge via email, the data will be provided to the researchers.

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Nima Nazari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Children's Medical Center Hospital, Dr,Gharib St, Keshavarz Blv</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733151</zip>
        <telephone>00982161479</telephone>
        <email>n-nazari@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nima Nazari</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Children's Medical Center Hospital, Dr.Gharib St, Keshavarz Blv</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1419733151</zip>
        <telephone>00982161479</telephone>
        <email>n-nazari@sina.tums.ac.ir</email>
        <affiliation>Tehran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>All children from 3 to 8 years old
Candidate for bilateral inguinal hernia surgery
Under general anesthesia
ASA class 1 and 2</inclusion_criteria>
      <agemin>3 years</agemin>
      <agemax>8 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Allergy to local anesthetics
Non-Persian speaking patients
Sacral infection
Coagulation disorders
History of seizures
Weight more than 20 kg
Patients who are being treated with a variety of painkillers and psychiatric medications for any reason</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: Patient under bilateral ilioinguinal block with rupivacaine 0.2%( manufactured by MOLTENI farmaceutici) under ultrasound guide. After determining the sedation score according to Ramsay criteria, patients are directed to the operating room. After installing standard monitoring equipment and obtaining a peripheral vein, 2 mg/kg sodium thiopental and 1 μg/kg fentanyl m is prescribed. Induction of anesthesia will be done by mapleson and under spontaneous inhalation. sevoflurane 8% and 100% oxgygen will be used in induction. After endotracheal tube insertion, maintenance of anesthesia will be provided by 100% oxygen and isoflurane 2.5%. After induction of anesthesia, heart rate and mean arterial pressure will be measured and recorded.In performing ilio-inguinal block, the child is in the supine position and after prep and drape a short 24G needle will be used. Rupivacaine 0.2% at a dose of 0.1 ml / kg will be used for drug injection. In case of increased heart rate or systolic blood pressure after incision by more than 20% of basal values, fentanyl will be repeated and recorded at a dose of 1 μg /kg. After surgery, the patient's pain intensity will be assessed using the CHEOPS criteria and the delirium score will be assessed by PAED score. In post anesthesia care unit, patients with CHEOPS pain score greater than 10 will be prescribed 1 of fentanyl  μg /kg.Rupivacaine is from the Bioindustria L.i.m.s.p.a brand.</i_keyword>
      <i_keyword>Intervention group 2: Patients under caudal block with rupivacaine 0.2%. After determining the sedation score according to Ramsay criteria, patients are directed to the operating room. After installing standard monitoring equipment and obtaining a peripheral vein, 2 mg/kg sodium thiopental and 1 μg/kg fentanyl m is prescribed. Induction of anesthesia will be done by mapleson and under spontaneous inhalation. sevoflurane 8% and 100% oxgygen will be used in induction. After endotracheal tube insertion, maintenance of anesthesia will be provided by 100% oxygen and isoflurane 2.5%. After induction of anesthesia, heart rate and mean arterial pressure will be measured and recorded./In performing ilio-inguinal block, the child is in the supine position and after prep and drape a short 24G needle will be used. Rupivacaine 0.2% at a dose of 0.1 ml. In the second group, the child is in a lateral position,The hip will flex and the lower leg will flex. After prep and drape, a short 24G needle was used Rupivacaine 0.2% at a dose of 1 ml / kg will be used.In case of increased heart rate or systolic blood pressure after incision by more than 20% of basal values, fentanyl will be repeated and recorded at a dose of 1 μg /kg. After surgery, the patient's pain intensity will be assessed using the CHEOPS criteria and the delirium score will be assessed by PAED score. In post anesthesia care unit, patients with CHEOPS pain score greater than 10 will be prescribed 1 of fentanyl  μg /kg.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Pain score based on CHEOPS criteria. Timepoint: After the patient enters the recovery ward, the pain score is recorded. Method of measurement: Children's Hospital of Eastern Ontario Pain Scale.</prim_outcome>
      <prim_outcome>PAED Delirium Score. Timepoint: After the patient enters the recovery ward, it is recorded. Method of measurement: It is obtained based on The Pediatric Anesthesia Emergence Delirium  criteria.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Recovery time. Timepoint: It is recorded and calculated between the time the patient enters the recovery ward and the patient leaves it. Method of measurement: It is recorded and calculated between the time the patient enters the recovery ward and the patient leaves it.</sec_outcome>
      <sec_outcome>Need for additional drugs (fentanyl). Timepoint: Additional dose of fentanyl prescribed after surgical incision or in the recovery ward. Method of measurement: Additional dose of fentanyl prescribed after surgical incision or in the recovery ward in micrograms per kilogram.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Tehran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2021-03-30</approval_date>
        <contact_name>Research Etichs Committee of Tehran University Of Medical Sciences</contact_name>
        <contact_address>Qods St, Keshavarz Blv Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
